Cucurbitacin B synergistically enhances the apoptosis-inducing effect of arsenic trioxide by inhibiting STAT3 phosphorylation in lymphoma Ramos cells

References

• Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005;23:2396–2410.
   PubMed Web of Science ®Google Scholar
• Chen SJ, Zhou GB, Zhang XW, et al. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood. 2011;117:6425–6437.
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Akay C. Arsenic trioxide: an anticancer missile with multiple warheads. Hematology. 2005;10:205–213.
   PubMed Web of Science ®Google Scholar
• Bonati A, Rizzoli V, Lunghi P. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol. 2006;7:397–405.
   PubMed Web of Science ®Google Scholar
• Fresquet V, Rieger M, Carolis C, et al. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014;123:4111–4119.
   PubMed Web of Science ®Google Scholar
• Kunkalla K, Liu YD, Qu CJ, et al. Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype. Ann Hematol. 2013;92:777–787.
   PubMed Web of Science ®Google Scholar
• Maxwell SA, Mousavi-Fard S. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance. Exp Biol Med (Maywood). 2013;238:971–990.
   PubMed Web of Science ®Google Scholar
• Choi JH, Ahn MJ, Park CK, et al. Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray. APMIS. 2006;114:619–625.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Kaestel CG, Eriksen KW, et al. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia. 1999;13:735–738.
   PubMed Web of Science ®Google Scholar
• Huang X, Meng B, Iqbal J, et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2013;31:4520–4528.
   PubMed Web of Science ®Google Scholar
• Doudican NA, Wen SY, Mazumder A, et al. Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways. Oncol Rep. 2012;28:1851–1858.
   PubMed Web of Science ®Google Scholar
• Lu KH, Lee HJ, Huang ML, et al. Synergistic apoptosis-inducing antileukemic effects of arsenic trioxide and Mucuna macrocarpa stem extract in human leukemic cells via a reactive oxygen species-dependent mechanism. Evid Based Complement Alternat Med. 2012;2012:921430.
   PubMed Web of Science ®Google Scholar
• Ramos AM, Fernandez C, Amran D, et al. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood. 2005;105:4013–4020.
   PubMed Web of Science ®Google Scholar
• Yousefi M, Ghaffari SH, Zekri A, et al. Differential sensitivity of p44/p42-MAPK- and PI3K/Akt-targeted neuroblastoma subtypes to arsenic trioxide. Neurochem Int. 2013;63:809–817.
   PubMed Web of Science ®Google Scholar
• Wakimoto N, Yin D, O'kelly J, et al. Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci. 2008;99:1793–1797.
   PubMed Web of Science ®Google Scholar
• Tannin-Spitz T, Grossman S, Dovrat S, et al. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol. 2007;73:56–67.
   PubMed Web of Science ®Google Scholar
• Kim SR, Seo HS, Choi HS, et al. Trichosanthes kirilowii ethanol extract and cucurbitacin D inhibit cell growth and induce apoptosis through inhibition of STAT3 activity in breast cancer cells. Evid Based Complement Alternat Med. 2013;2013:975350.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang M, Zhang H, et al. Combined antitumor activity of Cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol. 2008;587:78–84.
   PubMed Web of Science ®Google Scholar
• Thoennissen NH, Iwanski GB, Doan NB, et al. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res. 2009;69:5876–5884.
   PubMed Web of Science ®Google Scholar
• Lee DH, Iwanski GB, Thoennissen NH. Cucurbitacin: ancient compound shedding new light on cancer treatment. Sci World J. 2010;10:413–418.
   Web of Science ®Google Scholar
• Chan KT, Li K, Liu SL, et al. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett. 2010;289:46–52.
   PubMed Web of Science ®Google Scholar
• Haritunians T, Gueller S, Zhang L, et al. Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res. 2008;32:1366–1373.
   PubMed Web of Science ®Google Scholar
• Fan XM, Chen G, Sha Y, et al. Chemical constituents from the fruits of Trichosanthes kirilowii. J Asian Nat Prod Res. 2012;14:528–532.
   PubMed Web of Science ®Google Scholar
• Oh H, Mun YJ, Im SJ, et al. Cucurbitacins from Trichosanthes kirilowii as the inhibitory components on tyrosinase activity and melanin synthesis of B16/F10 melanoma cells. Planta Med. 2002;68:832–833.
   PubMed Web of Science ®Google Scholar
• Chen JC, Chiu MH, Nie RL, et al. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep. 2005;22:386–399.
   PubMed Web of Science ®Google Scholar
• Ma J, Zi Jiang Y, Shi H, et al. Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1α. Eur J Pharmacol. 2014;723:46–54.
   PubMed Web of Science ®Google Scholar
• Dakeng S, Duangmano S, Jiratchariyakul W, et al. Inhibition of Wnt signaling by Cucurbitacin B in breast cancer cells: reduction of Wnt-associated proteins and reduced translocation of galectin-3-mediated β-catenin to the nucleus. J Cell Biochem. 2012;113:49–60.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res. 2010;70:440–446.
   PubMed Web of Science ®Google Scholar
• Takemoto DJ. Effect of trichosanthin an anti-leukemia protein on normal mouse spleen cells. Anticancer Res. 1998;18:357–361.
   PubMed Web of Science ®Google Scholar
• Sha O, Niu J, Ng TB, et al. Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review. Cancer Chemother Pharmacol. 2013;71:1387–1393.
   PubMed Web of Science ®Google Scholar
• Chen X, Bao J, Guo J, et al. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. Anticancer Drugs. 2012;23:777–787.
   PubMed Web of Science ®Google Scholar
• Guo J, Wu G, Bao J, et al. Cucurbitacin B induced ATM-mediated DNA damage causes G2/M cell cycle arrest in a ROS-dependent manner. PLoS One. 2014;9:e88140.
   PubMed Web of Science ®Google Scholar
• Jin HR, Jin X, Dat NT, et al. Cucurbitacin B suppresses the transactivation activity of RelA/p65. J Cell Biochem. 2011;112:1643–1650.
   PubMed Web of Science ®Google Scholar
• Gupta P, Srivastava SK. Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget. 2014;5:1812–1828.
   PubMed Web of Science ®Google Scholar
• Metcalf RL. Coevolutionary adaptations of rootworm beetles (Coleoptera: Chrysomelidae) to cucurbitacins. J Chem Ecol. 1986;12:1109–1124.
   PubMed Web of Science ®Google Scholar
• Raikhlin-Eisenkraft B, Bentur Y. Ecbalium elaterium (squirting cucumber)-remedy or poison? J Toxicol Clin Toxicol. 2000;38:305–308.
   PubMed Web of Science ®Google Scholar
• Chang JE, Voorhees PM, Kolesar JM, et al. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol. 2009;27:11–16.
   PubMed Web of Science ®Google Scholar
• Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003;101:1535–1542.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Ray RM, Johnson LR. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J. 2005;392:335–344.
   PubMed Web of Science ®Google Scholar
• Zhao J, Xu Y, Zong Y, et al. Inhibition of Stat3 expression induces apoptosis and suppresses proliferation in human leukemia HL-60 cells. Hematology. 2011;16:232–235.
   PubMed Web of Science ®Google Scholar
• Miyagaki T, Sugaya M, Murakami T, et al. CCL11–CCR3 interactions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation. Cancer Res. 2011;71:2056–2065.
   PubMed Web of Science ®Google Scholar
• Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009;16:368–377.
   PubMed Web of Science ®Google Scholar
• Shi X, Franko B, Frantz C, et al. JSI-124 (Cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br J Haematol. 2006;135:26–32.
   PubMed Web of Science ®Google Scholar
• Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 1997;34:9–19.
   PubMed Web of Science ®Google Scholar
• Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 2008;111:3322–3330.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;81:151–157.
   PubMed Web of Science ®Google Scholar